Buckley Peter F, Wirshing Donna A, Bhushan Prameet, Pierre Joseph M, Resnick Seth A, Wirshing William C
Department of Psychiatry, Medical College of Georgia, 1515 Pope Avenue, Augusta, Georgia 30912, USA.
CNS Drugs. 2007;21(2):129-41. doi: 10.2165/00023210-200721020-00004.
People with schizophrenia commonly lack insight, that is, they are unaware of their illness and the consequences thereof. One of the most important consequences of lack of insight is a failure to recognise the need for treatment, leading to treatment nonadherence. With several scales that now enable objective measurement of insight, it is possible to examine correlates of insight change, including course of illness and treatment adherence. Specific interventions, both pharmacological and psychotherapeutic, have been developed to enhance illness insight and treatment adherence. The extent to which second-generation antipsychotic medications, including a recently released long-acting formulation, improve insight and/or enhance treatment adherence remains to be determined.
精神分裂症患者通常缺乏自知力,也就是说,他们没有意识到自己的病情及其后果。缺乏自知力最重要的后果之一是未能认识到治疗的必要性,从而导致治疗依从性差。现在有几种量表能够客观地测量自知力,因此可以研究自知力变化的相关因素,包括病程和治疗依从性。已经开发了包括药物治疗和心理治疗在内的特定干预措施,以增强对疾病的自知力和治疗依从性。包括最近发布的长效制剂在内的第二代抗精神病药物在多大程度上能改善自知力和/或增强治疗依从性仍有待确定。